SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Wallentin Lars C. 1943 ) "

Sökning: WFRF:(Wallentin Lars C. 1943 )

  • Resultat 41-50 av 87
  • Föregående 1...234[5]678...9Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  • Held, Claes, 1956-, et al. (författare)
  • Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease : Insights from the STABILITY trial
  • 2018
  • Ingår i: American Heart Journal. - 0002-8703 .- 1097-6744. ; 208, s. 65-73
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Clinical Endpoint Classification (CEC) in clinical trials allows FOR standardized, systematic, blinded, and unbiased adjudication of investigator-reported events. We quantified the agreement rates in the STABILITY trial on 15,828 patients with stable coronary heart disease.METHODS: Investigators were instructed to report all potential events. Each reported event was reviewed independently by 2 reviewers according to prespecified processes and prespecified end point definitions. Concordance between reported and adjudicated cardiovascular (CV) events was evaluated, as well as event classification influence on final study results.RESULTS: In total, CEC reviewed 7,096 events: 1,064 deaths (696 CV deaths), 958 myocardial infarctions (MI), 433 strokes, 182 transient ischemic attacks, 2,052 coronary revascularizations, 1,407 hospitalizations for unstable angina, and 967 hospitalizations for heart failure. In total, 71.8% events were confirmed by CEC. Concordance was high (>80%) for cause of death and nonfatal MI and lower for hospitalization for unstable angina (25%) and heart failure (50%). For the primary outcome (composite of CV death, MI, and stroke), investigators reported 2,086 events with 82.5% confirmed by CEC. The STABILITY trial treatment effect of darapladib versus placebo on the primary outcome was consistent using investigator-reported events (hazard ratio 0.96 [95% CI 0.87-1.06]) or adjudicated events (hazard ratio 0.94 [95% CI 0.85-1.03]).CONCLUSIONS: The primary outcome results of the STABILITY trial were consistent whether using investigator-reported or CEC-adjudicated events. The proportion of investigator-reported events confirmed by CEC varied by type of event. These results should help improve event identification in clinical trials to optimize ascertainment and adjudication.
  •  
42.
  • Hernández, Adrián V., et al. (författare)
  • Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes : benefit and harm in different age subgroups
  • 2007
  • Ingår i: Heart. - 1355-6037 .- 1468-201X. ; 93:4, s. 450-455
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To investigate whether the beneficial and harmful effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST elevation acute coronary syndromes (NSTE-ACS) depend on age. METHODS: A meta-analysis of six trials of platelet glycoprotein IIb/IIIa receptor blockers in patients with NSTE-ACS (PRISM, PRISM-PLUS, PARAGON-A, PURSUIT, PARAGON-B, GUSTO IV-ACS; n = 31 402) was performed. We applied multivariable logistic regression analyses to evaluate the drug effects on death or non-fatal myocardial infarction at 30 days, and on major bleeding, by age subgroups (<60, 60-69, 70-79, > or =80 years). We quantified the reduction of death or myocardial infarction as the number needed to treat (NNT), and the increase of major bleeding as the number needed to harm (NNH). RESULTS: Subgroups had 11 155 (35%), 9727 (31%), 8468 (27%) and 2049 (7%) patients, respectively. The relative benefit of platelet glycoprotein IIb/IIIa receptor blockers did not differ significantly (p = 0.5) between age subgroups (OR (95% CI) for death or myocardial infarction: 0.86 (0.74 to 0.99), 0.90 (0.80 to 1.02), 0.97 (0.86 to 1.10), 0.90 (0.73 to 1.16); overall 0.91 (0.86 to 0.99). ORs for major bleeding were 1.9 (1.3 to 2.8), 1.9 (1.4 to 2.7), 1.6 (1.2 to 2.1) and 2.5 (1.5-4.1). Overall NNT was 105, and overall NNH was 90. The oldest patients had larger absolute increases in major bleeding, but also had the largest absolute reductions of death or myocardial infarction. Patients > or =80 years had half of the NNT and a third of the NNH of patients <60 years. CONCLUSIONS: In patients with NSTE-ACS, the relative reduction of death or non-fatal myocardial infarction with platelet glycoprotein IIb/IIIa receptor blockers was independent of patient age. Larger absolute outcome reductions were seen in older patients, but with a higher risk of major bleeding. Close monitoring of these patients is warranted.
  •  
43.
  • Hjort, Marcus, 1988-, et al. (författare)
  • Biomarker concentrations and their temporal changes in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries: results from the PLATelet inhibition and patient Outcomes (PLATO) trial
  • Annan publikation (övrigt vetenskapligt)abstract
    • BACKGROUND: The pathobiology of myocardial infarction (MI) with non-obstructive coronary arteries (MINOCA) is often uncertain. We aimed at exploring whether biomarker concentrations during the acute disease phase and their one-month changes may offer novel pathophysiological insights.METHODS: In this observational post-hoc study of the PLATelet inhibition and patient Outcomes (PLATO) trial, plasma concentrations of high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP) and growth differentiation factor 15 (GDF-15) were measured in MINOCA patients at baseline (n=554) and after one month (n=107). For comparisons, biomarkers were also measured in patients with MI and obstructive (stenosis ≥50%) coronary arteries (MI-CAD [baseline: n=11,106; one month: n=2755]). Adjusted linear regression models were mainly used to compare concentrations at both time points.RESULTS: MINOCA patients (median age 61 years; 50.4% females) presented less often with ST-elevation (25.6% versus 49.4%) and had longer time from symptom onset to blood sampling (median 15.1 versus 8.9 hours) than MI-CAD. Adjusted geometric mean ratios (GMR) indicated lower hs-cTnT concentrations (GMR 0.77 [95% confidence interval [CI] 0.68-0.88]) but higher hs-CRP (GMR 1.21 [95% CI 1.08-1.37]) and GDF-15 concentrations (GMR 1.06 [95% CI 1.02-1.11]) at baseline in MINOCA compared to MI-CAD. Baseline NT-proBNP concentrations were similar between MI groups. Temporal decreases in hs-cTnT, NT-proBNP and hs-CRP concentrations until one month were more pronounced in MINOCA than MI-CAD. At one month, MINOCA had lower concentrations of hs-cTnT (GMR 0.71 [95% CI 0.60-0.84]), NT-proBNP (GMR 0.45 [95% CI 0.36-0.56]) and hs-CRP (GMR 0.68 [95% CI 0.53-0.86]). One-month GDF-15 concentrations were similar in both MI groups. CONCLUSIONS: Biomarker concentrations suggest greater initial inflammatory activity, similar myocardial dysfunction and less pronounced myocardial injury during the acute phase of MINOCA compared to MI-CAD. Their temporal changes also indicated faster recovery in MINOCA.CLINICAL TRAIL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00391872.
  •  
44.
  •  
45.
  • Kempf, Tibor, et al. (författare)
  • Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay
  • 2007
  • Ingår i: Clinical Chemistry. - 0009-9147 .- 1530-8561. ; 53:2, s. 284-291
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Growth-differentiation factor 15 (GDF15) is a member of the transforming growth factor beta (TGF-beta) cytokine superfamily. There has been increasing interest in using circulating GDF15 as a biomarker in patients, for example those with cardiovascular disease. METHODS: We developed an IRMA that uses a polyclonal, affinity chromatography-purified goat antihuman GDF15 IgG antibody, assessed the preanalytic characteristics of GDF15, and determined circulating GDF15 concentrations in 429 apparently healthy elderly individuals and 153 patients with chronic heart failure (CHF). RESULTS: The assay had a detection limit of 20 ng/L, an intraassay imprecision of < or =10.6%, and an interassay imprecision of < or =12.2%. Specificity was demonstrated with size-exclusion chromatography, parallel measurements with polyclonal and monoclonal anti-GDF15 antibody, and lack of cross-reactivity with TGF-beta. The assay was not appreciably influenced by the anticoagulant matrix or unrelated biological substances. GDF15 was stable at room temperature for 48 h and resistant to 4 freeze-thaw cycles. Apparently healthy, elderly individuals presented with a median GDF15 concentration of 762 ng/L (25th-75th percentiles, 600-959 ng/L). GDF15 concentrations were associated with age and with cystatin C and C-reactive protein concentrations. CHF patients had increased GDF15 concentrations that were closely related to disease severity. CONCLUSION: The IRMA can detect GDF15 in human serum and plasma with excellent sensitivity and specificity. The reference limits and confounding variables defined for apparently healthy elderly individuals and the favorable preanalytic characteristics of GDF15 are expected to facilitate future studies of GDF15 as a biomarker in various disease settings, including CHF.
  •  
46.
  • Kempf, Tibor, et al. (författare)
  • Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction
  • 2007
  • Ingår i: European Heart Journal. - 0195-668X .- 1522-9645. ; 28:23, s. 2858-2865
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims Growth-differentiation factor-15 (GDF-15) is a transforming growth factor-beta-related cytokine that is induced in the heart following ischaemia-reperfusion injury. We explored the prognostic utility of GDF-15 in patients with ST-segment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy. Methods and results Circulating levels of GDF-15 were determined by an immunoradiometric assay in 741 STEMI patients who were included in the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-2 and ASSENT-plus trials. About 72.7% of the patients presented with GDF-15 levels >= 1200 ng/L, the upper limit of normal in apparently healthy elderly individuals. Increased levels of GDF-15 were associated with a higher risk of death during 1-year follow-up. Mortality rates at 1 year were 2.1, 5.0, and 14.0% in patients with GDF-15 levels < 1200, 1200-1800, and > 1800 ng/L, respectively (P < 0.001). GDF-15 remained an independent predictor of mortality after adjustment for clinical variables, troponin T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). GDF-15 provided prognostic information in clinically relevant patient subgroups, defined according to age, gender, cardiovascular risk factors, haemodynamic status, and the TIMI risk score. Moreover, GDF-15 added prognostic information to the established biomarkers of adverse prognosis in STEMI, troponin T, and NT-proBNP. Conclusion GDF-15 is a new biomarker in STEMI that provides prognostic information beyond established clinical and biochemical markers.
  •  
47.
  • Kessler, Thorsten, et al. (författare)
  • Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention
  • 2019
  • Ingår i: Cardiovascular Research. - : OXFORD UNIV PRESS. - 0008-6363 .- 1755-3245. ; 115:10, s. 1512-1518
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim A common genetic variant at the GUCY1A3 coronary artery disease locus has been shown to influence platelet aggregation. The risk of ischaemic events including stent thrombosis varies with the efficacy of aspirin to inhibit platelet reactivity. This study sought to investigate whether homozygous GUCY1A3 (rs7692387) risk allele carriers display higher on-aspirin platelet reactivity and risk of ischaemic events early after coronary intervention. Methods and results The association of GUCY1A3 genotype and on-aspirin platelet reactivity was analysed in the genetics substudy of the ISAR-ASPI registry (n = 1678) using impedance aggregometry. The clinical outcome cardiovascular death or stent thrombosis within 30 days after stenting was investigated in a meta-analysis of substudies of the ISAR-ASPI registry, the PLATO trial (n = 3236), and the Utrecht Coronary Biobank (n = 1003) comprising a total 5917 patients. Homozygous GUCY1A3 risk allele carriers (GG) displayed increased on-aspirin platelet reactivity compared with non-risk allele (AA/AG) carriers [150 (interquartile range 91-209) vs. 134 (85-194) AU.min, P < 0.01]. More homozygous risk allele carriers, compared with non-risk allele carriers, were assigned to the high-risk group for ischaemic events (>203AU.min; 29.5 vs. 24.2%, P = 0.02). Homozygous risk allele carriers were also at higher risk for cardiovascular death or stent thrombosis (hazard ratio 1.70, 95% confidence interval 1.08-2.68; P = 0.02). Bleeding risk was not altered. Conclusion We conclude that homozygous GUCY1A3 risk allele carriers are at increased risk of cardiovascular death or stent thrombosis within 30 days after coronary stenting, likely due to higher on-aspirin platelet reactivity. Whether GUCY1A3 genotype helps to tailor antiplatelet treatment remains to be investigated.
  •  
48.
  • Kloosterman, Marielle, et al. (författare)
  • Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors : an RE-LY AF registry analysis
  • 2020
  • Ingår i: Europace. - 1099-5129 .- 1532-2092. ; 22:6, s. 870-877
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims: Data on patient characteristics, prevalence, and outcomes of atrial fibrillation (AF) patients without traditional risk factors, often labelled 'lone AF', are sparse. Methods and results: The RE-LY AF registry included 15 400 individuals who presented to emergency departments with AF in 47 countries. This analysis focused on patients without traditional risk factors, including age >= 60years, hypertension, coronary artery disease, heart failure, left ventricular hypertrophy, congenital heart disease, pulmonary disease, valve heart disease, hyperthyroidism, and prior cardiac surgery. Patients without traditional risk factors were compared with age- and region-matched controls with traditional risk factors (1:3 fashion). In 796 (5%) patients, no traditional risk factors were present. However, 98% (779/796) had less-established or borderline risk factors, including borderline hypertension (130-140/80-90mmHg; 47%), chronic kidney disease (eGFR<60mL/min; 57%), obesity (body mass index>30; 19%), diabetes (5%), excessive alcohol intake (>14 units/week; 4%), and smoking (25%). Compared with patients with traditional risk factors (n=2388), patients without traditional risk factors were more often men (74% vs. 59%, P<0.001) had paroxysmal AF (55% vs. 37%, P<0.001) and less AF persistence after 1 year (21% vs. 49%, P<0.001). Furthermore, 1-year stroke occurrence rate (0.6% vs. 2.0%, P=0.013) and heart failure hospitalizations (0.9% vs. 12.5%, P<0.001) were lower. However, risk of AF-related re-hospitalization was similar (18% vs. 21%, P=0.09). Conclusion: Almost all patients without traditionally defined AF risk factors have less-established or borderline risk factors. These patients have a favourable 1-year prognosis, but risk of AF-related re-hospitalization remains high. Greater emphasis should be placed on recognition and management of less-established or borderline risk factors.
  •  
49.
  • Kolb, Jennifer M., et al. (författare)
  • Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran
  • 2018
  • Ingår i: Digestive Diseases and Sciences. - : SPRINGER. - 0163-2116 .- 1573-2568. ; 63:7, s. 1878-1889
  • Tidskriftsartikel (refereegranskat)abstract
    • Different oral anticoagulants may be associated with gastrointestinal bleeding (GIB) from different locations or mucosal lesions. We aimed to test this hypothesis. Two blinded gastroenterologists independently analyzed source documents from the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial of dabigatran 150 mg BID (D150), dabigatran 110 mg BID (D110) versus warfarin in non-valvular atrial fibrillation (NVAF). Major GIB events (total n = 546) and life-threatening GIB events (n = 258) were more common with D150 versus warfarin (RR 1.57 [1.28-1.92] and RR 1.62 [1.20-2.18], respectively) and similar for D110 compared to warfarin (RR 1.11 [0.89-1.38] and RR 1.16 [0.84-1.61], respectively). Fatal bleeding was similarly rare across treatment groups. Lower GI major bleeding and life-threatening bleeding were more common with D150 compared to warfarin (RR 2.23 [1.47, 3.38] and RR 2.64 [1.36, 5.13], respectively) and with D110 compared to warfarin (RR 1.78 [1.16, 2.75] and RR 2.00 [1.00, 4.00], respectively). MGIB from colonic angiodysplasia was increased with dabigatran versus warfarin (P < 0.01 for both dose comparisons). Subacute and chronic MGIB events were more common with D150 than with warfarin (RR 1.72 [1.06, 2.78] and RR 1.66 [1.12, 2.45], respectively), as were hematochezia or melena (RR 1.67 [1.18, 2.36] and RR 1.72 [1.20, 2.47], respectively). In a chronic NVAF population, D150 but not D110 is associated with increased major and life-threatening GI bleeding in comparison with warfarin. At both dabigatran doses, increased bleeding from the colorectum, in particular from angiodysplasia, is seen.
  •  
50.
  • Kontny, Frederic, et al. (författare)
  • Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome : A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial
  • 2020
  • Ingår i: European heart journal. Acute cardiovascular care.. - 2048-8726. ; 9:4, s. 313-322
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS: We investigated the dynamics, associations with patient characteristics, other biomarkers, and clinical outcomes of pentraxin 3 in acute coronary syndrome.METHODS AND RESULTS: In multivariate analyses, pentraxin 3 measured in 5154 patients randomised in the Platelet Inhibition and Patients Outcomes (PLATO) trial (NCT00391872) was compared with leukocytes, high-sensitivity C-reactive protein, interleukin-6, cystatin C, N-terminal prohormone brain natriuretic peptide, high-sensitivity troponin T and growth differentiation factor 15 concerning prediction of clinical outcome. Pentraxin 3 peaked earlier than high-sensitivity C-reactive protein and was more strongly correlated with N-terminal prohormone brain natriuretic peptide and high-sensitivity troponin T than with high-sensitivity C-reactive protein. The frequency of cardiovascular death, spontaneous myocardial infarction or stroke by quartiles of pentraxin 3 at admission was 6.1%, 7.3%, 9.7% and 10.7%, respectively ( p<0.0001). The hazard ratio per 50% increase of pentraxin 3 was 1.13 (95% confidence interval: 1.07-1.19), p<0.0001. This association remained significant after stepwise adjustments for leukocytes/high-sensitivity C-reactive protein (1.09 (1.02-1.15)), p=0.009, interleukin-6 (1.07 (1.01-1.14)), p=0.026, and cystatin C (1.07 (1.00-1.13)), p=0.044, but not after adjustment for N-terminal prohormone brain natriuretic peptide, high-sensitivity troponin T and growth differentiation factor 15. Admission pentraxin 3 was also associated with several of the individual endpoint components (cardiovascular death/spontaneous myocardial infarction; p=0.008, cardiovascular death; p=0.026, and spontaneous myocardial infarction; p=0.017), but not with stroke. Pentraxin 3 measured in the chronic phase (i.e. at one month) was still predictive of the composite endpoint in univariate analysis (1.12 (1.04-1.20) per 50% increase) p=0.0024, but not after adjustment for the other biomarkers.CONCLUSION: Admission level of pentraxin 3 is a modestly stronger predictor than high-sensitivity C-reactive protein and interleukin-6, but not than N-terminal prohormone brain natriuretic peptide or high-sensitivity troponin T, concerning cardiovascular outcome in acute coronary syndrome. Pentraxin 3 is more strongly correlated with N-terminal prohormone brain natriuretic peptide and high-sensitivity troponin T than with high-sensitivity C-reactive protein.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 41-50 av 87
  • Föregående 1...234[5]678...9Nästa
Typ av publikation
tidskriftsartikel (84)
forskningsöversikt (2)
annan publikation (1)
Typ av innehåll
refereegranskat (75)
övrigt vetenskapligt (12)
Författare/redaktör
Wallentin, Lars, 194 ... (77)
Storey, Robert F. (30)
Becker, Richard C. (30)
James, Stefan K., 19 ... (19)
Himmelmann, Anders (18)
Held, Claes, 1956- (17)
visa fler...
James, Stefan, 1964- (17)
Cannon, Christopher ... (17)
Siegbahn, Agneta, 19 ... (16)
Åkerblom, Axel, 1977 ... (16)
Katus, Hugo A (14)
Steg, Philippe Gabri ... (14)
Husted, Steen (12)
Harrington, Robert A (10)
Lindahl, Bertil, 195 ... (10)
Mahaffey, Kenneth W. (10)
Granger, C. B. (9)
Budaj, Andrzej (9)
Siegbahn, Agneta (8)
Hagström, Emil (8)
Armstrong, Paul W. (8)
Lopes, Renato D. (8)
White, Harvey D. (8)
Kontny, Frederic (8)
Alexander, J. H. (7)
Boerwinkle, Eric (7)
Sattar, Naveed (6)
Ueland, Thor (6)
Bertilsson, Maria (6)
Nikus, Kjell (6)
Michelsen, Annika E. (6)
Horrow, Jay (6)
Tragante, Vinicius (6)
Asselbergs, Folkert ... (6)
Koenig, Wolfgang (6)
Simoons, Maarten L (6)
Lind, Lars (5)
Trompet, Stella (5)
Jukema, J. Wouter (5)
Richards, A. Mark (5)
Alexander, John H. (5)
Fox, Keith A. A. (5)
Nelson, Christopher ... (5)
Samani, Nilesh J. (5)
Mohan, P. (5)
Cornel, Jan H. (5)
White, Harvey (5)
Gong, Yan (5)
Kleber, Marcus E. (5)
Spertus, John A. (5)
visa färre...
Lärosäte
Uppsala universitet (87)
Lunds universitet (5)
Linköpings universitet (2)
Karolinska Institutet (1)
Språk
Engelska (87)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (55)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy